Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Polyethylene Glycols × Gastrointestinal × Clear all

Phase

Phase NA 5 Phase 3 3 Phase 4 2 Phase EARLY_PHASE1 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Gastrointestinal 1 Dermatologic 1

Conditions

Liver Neoplasms 1

Interventions

Oxaliplatin 695 Fluorouracil 580 Capecitabine 504 Gemcitabine 426 Leucovorin 420 Irinotecan 402 Bevacizumab 397 Cisplatin 298 Radiotherapy 258 Cetuximab 224 S 1 (combination) 158 Paclitaxel 157 pembrolizumab 156 Docetaxel 144 Drug Therapy 127 Nivolumab 124 sintilimab 118 apatinib 118 tislelizumab 116 130-nm albumin-bound paclitaxel 111 durvalumab 109 Folfox protocol 105 Albumin-Bound Paclitaxel 99 Surgical Procedures, Operative 95 Panitumumab 95 camrelizumab 94 lenvatinib 93 Sorafenib 90 regorafenib 88 Radiation 81

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02006030 2018-09-04

TACE

Polaris Group

Phase 2 Completed

Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡